Shares of Alpha Cognition Inc. (OTC:ACOGF – Get Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as C$8.91 and last traded at C$8.40, with a volume of 4246 shares changing hands. The stock had previously closed at C$8.60.
Alpha Cognition Price Performance
The company has a market capitalization of C$1.27 billion, a price-to-earnings ratio of -70.00 and a beta of 2.80. The company has a 50 day simple moving average of C$1.05 and a 200 day simple moving average of C$0.71.
Alpha Cognition (OTC:ACOGF – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported C($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of C($0.04) by C$0.03. On average, research analysts forecast that Alpha Cognition Inc. will post -0.19 EPS for the current fiscal year.
Alpha Cognition Company Profile
Alpha Cognition Inc, a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.
Featured Stories
- Five stocks we like better than Alpha Cognition
- Best Stocks Under $5.00
- Rocket Lab is the Right Stock for the Right Time
- About the Markup Calculator
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- High Flyers: 3 Natural Gas Stocks for March 2022
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
